Artis Ventures

Artis Ventures Research Investment Thesis Artis Ventures is a specialized venture capital firm focused on the intersection of technology and biology—a domain they pioneered by coining and trademarking the term "TechBio®." The firm invests in early-stage companies that leverage frontier technologies (AI, gene editing, synthetic biology, advanced diagnostics) to transform human health, cure disease, and strengthen global resilience. Their thesis centers on the belief that data-driven, engineering-first approaches combined with cellular biology create the next generation of transformative healthcare companies. The firm explicitly targets companies solving problems affecting everyday people globally, with a particular focus on companies that can apply multiple therapeutic or commercial pathways from a single biologically-engineered platform, enabling increased revenue streams, optionality, and intellectual property flexibility. Investment Strategy & Philosophy TechBio Convergence: Artis identifies seven key tailwinds driving innovation in TechBio: Collapsing OMICS sequencing costs enabling "open source" science and R&D Digitization of biology converting biological data into computable information Increasing business development in life sciences (corporates acquiring innovation) Expanded data creation and advanced computing (e.g., AlphaFold2 expanded protein structures 200x) Better knowledge of biological processes enabling personalized, in-vivo medicine Skyrocketing drug development costs ($1.3B average, $2.8B for oncology/immunology) driving cost reduction innovation Growing cloud storage infrastructure enabling genomics data utilization Investment Approach: The firm combines deep domain expertise with operational support. They invested early in YouTube, Facebook, StemCentRx, Cohesity, and Palantir, demonstrating track record with both foundational and applied TechBio companies. Founder Support: Artis provides value through: Embedded "Fellows Program" placing MDs, PhDs, and subject matter experts as in-house scientific brain trust Pioneers Network of global leaders and visionaries Healthcare Alliance connecting portfolio companies with industry partners Strategic support for companies pivoting across multiple indications Investment Sectors & Technology Focus Primary Disease Areas Oncology (cell therapies, precision medicine, targeted therapeutics) Infectious disease (CRISPR-based therapies, antimicrobial innovation) Neurology & Mental Health (neuroplasticity therapeutics, addiction recovery) Women's Health (fertility, maternal health, reproductive science) Cardiopulmonary & Metabolic disease Immunology (cell therapies, immunotherapies) Aging & Longevity Consumer Health (digital health, telehealth, wellness) Digestive Health & Gastrointestinal Technology Platforms Synthetic & Computation Biology : CRISPR gene editing, synthetic biology, protein engineering, macrocycle development, cell therapies, precision medicine Data & Compute : AI-assisted diagnostics, clinical decision support, data security, machine learning for drug discovery, genomics informatics Internet of TechBio (IoTB) : Medical devices, wearables, surgical intelligence, diagnostics hardware Clinical Medicine : Virtual healthcare delivery, clinical trial matching, medical simulation Key Technology Enablers AI/ML for drug discovery, diagnostics, clinical decision support Gene editing (CRISPR, AAV therapies, base editing) Synthetic biology and protein engineering Advanced diagnostics and biomarker discovery Computational biology and bioinformatics Medical device innovation Telehealth and digital health platforms Stage Focus & Check Size Investment Stages: Primary : Seed stage (early commercial traction with working products) Secondary : Series A (companies demonstrating product-market fit) Tertiary : Pre-seed and follow-on investments for exceptional founders Fund : TechBio Fund II (~$200M+, closed December 2023), actively deploying Check Size Range: Typical range: $50K - $25M Sweet spot: Seed-stage rounds ($1M-$10M range based on portfolio activity) Geographic Focus Primary: United States (based in San Francisco, California) with strong SF Bay Area biotech ecosystem presence Secondary: Global reach through Fellows and Pioneers networks, with portfolio companies and advisory relationships spanning internationally Portfolio Companies & Recent Activity Portfolio Scale 56+ confirmed portfolio companies across TechBio and healthcare innovation Recent Notable Activity Recent Investments (2024-2025): RadAI - AI-powered radiology insights ($25M Series A, October 2025) - Participated ONTO Health - Fertility, longevity, reproductive health - Seed Rad AI - Radiologist AI assistance - Series A (2025) Conceivable - Fertility science via genomics and AI diagnostics - Seed Delfina - Maternal health prediction and AI - Seed Excision - CRISPR-based therapies for viral infectious diseases - Seed Outpace Bio - Protein engineering for cell therapies - Seed Viacyte - Type 1 Diabetes functional cure - Seed Delix - Neuroplasticity-promoting therapeutics - Seed Historical Exits: StemCentRx (acquired by Juno/Celgene, 2015) YouTube (early-stage investment) Facebook (early-stage investment) Notable Portfolio: Palantir - Data analytics platform Cohesity - Data management and security Metriport - Patient medical data access Modern Meadow - Sustainable biomaterials Tessera Therapeutics - Gene therapy EKO - Cardiovascular monitoring devices Team & Leadership Stuart Peterson - Founder and Managing General Partner (UCLA, 1990; Chicago MBA, 1995). Forbes Midas List, 20+ years at firm, early investor in YouTube and Facebook. Ruchita Sinha - Senior Partner with 10+ years at Artis, expert in life sciences and biotech investments. Frequent speaker on seed/Series A biotech fundraising. Henry Klingenstein - Partner focused on healthcare technologies (Stanford MBA, 2023). Board observer at multiple portfolio companies. Jeff Sheedy - Partner based in San Francisco with focus on healthcare and biotech investments. Investment Decision Process Structure: Partnership model with Stuart Peterson leading strategy and senior deals, Ruchita Sinha and Henry Klingenstein providing domain expertise. Due Diligence: Leverages extensive network of scientific advisors, embedded Fellows program, and healthcare advisory network for technical validation. Timeline: Estimated 3-8 weeks for seed-stage decisions. Macro Context & Market Opportunity Artis positions early 2020s and beyond as exceptional moment for TechBio investing: Government Support & Policy Tailwinds: United States: $500B+ from IRA, CHIPS Act, Bipartisan Infrastructure Law Europe: $1.1T+ by 2030 from European Green Deal Corporate adoption: 40% of Fortune 500 with Net Zero targets Talent influx: PhD and scientist founders increasingly starting companies Market Dynamics: Scientific tailwinds: Collapsing sequencing costs, digitized biology, expanded computing Corporate M&A: Increasing acquisition of biotech innovation Data explosion: Genomics, proteomics, imaging creating new opportunities Reduced time-to-market: Exponential technologies accelerating TechBio commercialization Summary Artis Ventures is a specialized, thesis-driven early-stage venture capital firm with 20+ year track record of identifying transformative healthcare and enabling technology companies. Their focus on TechBio convergence—combining frontier technologies (AI, gene editing, synthetic biology) with deep biological understanding—positions them at the center of the next wave of healthcare disruption. With 56+ portfolio companies spanning diagnostics, therapeutics, medical devices, and digital health, Artis combines early-stage capital with scientific expertise through their embedded Fellows program and extensive healthcare advisory network.